Citius Pharmaceuticals’ Lymphir and Keytruda Combo Shows Promising Clinical Outcomes, Earning a Buy Rating
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
Cure Today6d
Keytruda Has Long-Term Survivorship Implications in Early Triple-Negative Breast Cancer
Among patients with early triple-negative breast cancer, treatment with Keytruda (pembrolizumab) demonstrated real-world evidence of immune-related adverse effects (irAEs) comparable with KEYNOTE-522, ...
Healthline8d
All About Keytruda
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...
Yahoo Finance13d
Merck earnings top estimates amid solid demand for Keytruda cancer drug
Investing.com -- Merck and Co. (NYSE:MRK) has posted better-than-anticipated third-quarter profit thanks to solid demand for its crucial cancer treatment Keytruda, although the drugmaker warned of ...
Business Insider6d
IO Biotech reports data on IO102-IO103 vaccine in combination with KEYTRUDA
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...
Cure Today29d
Keytruda Regimen May Improve Event-Free Survival in Head and Neck Squamous Cell Carcinoma
KEYNOTE-689 trial showed significant improvement in event-free survival for stage 3 or 4A resected head and neck squamous cell carcinoma with Keytruda. Keytruda regimen included neoadjuvant therapy, ...
pharmaphorum12d
Merck gets FDA okay for Keytruda as liver cancer therapy
Merck & Co/MSD has won approval in the US for PD-1 inhibitor Keytruda as a treatment for hepatocellular carcinoma (HCC), the most common form of liver cancer, opening up another front in its ...
Nasdaq20d
Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers
KEYTRUDA plus chemotherapy is the first approval in the EU for an anti-PD-1 therapy combined with chemotherapy only for patients with primary advanced or recurrent endometrial carcinoma regardless ...
Yahoo Finance25d
Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best medical stocks to ...
The Pharma Letter13d
Merck slips as relentless Keytruda cancelled out by Gardasil dip
Shares in Merck & Co (NYSE: MRK) were more than 2% lower as New York trading entered its latter half on Thursday. The US pharma giant earlier announced its financial results for the third quarter of ...
Merck & Co. (MRK): Strong Growth Driven by Keytruda and New Vaccine Approvals
Its top-selling cancer drug, Keytruda, is a standout product with global recognition. In Q2 2024, Merck & Co., Inc. (NYSE:MRK ...